Author: Wu Liu; Mehmet U. Caglar; Zhangming Mao; Andrew Woodman; Jamie J. Arnold; Claus O. Wilke; Craig E. Cameron
Title: More than efficacy revealed by single-cell analysis of antiviral therapeutics Document date: 2019_4_12
ID: aiyg061l_26
Snippet: The three classes of antiviral therapeutics chosen target a viral polymerase (2'-C-286 methyladenosine, 2'-C- Me-A, Fig. S4) , a viral protease (rupintrivir, Fig. 2) , or a host factor, 287 HSP90, (geldanamycin, GA, Fig. 3; ganetespib, GS, Fig. S6 ). Our data-analysis pipeline 288 emphasizes five phenomenological parameters with correlates to traditional parameters for 289 assessment of the viral lifecycle. 7 The major finding of this study is th.....
Document: The three classes of antiviral therapeutics chosen target a viral polymerase (2'-C-286 methyladenosine, 2'-C- Me-A, Fig. S4) , a viral protease (rupintrivir, Fig. 2) , or a host factor, 287 HSP90, (geldanamycin, GA, Fig. 3; ganetespib, GS, Fig. S6 ). Our data-analysis pipeline 288 emphasizes five phenomenological parameters with correlates to traditional parameters for 289 assessment of the viral lifecycle. 7 The major finding of this study is that each class of antiviral 290 therapeutics exhibited a unique signature with respect to the five phenomenological parameters 291 measured and so much so that it was possible to use principal component analysis (PCA) to 292 stratify the different therapeutic classes (Fig. 5) . Importantly, both GA and GS overlapped by 293 PCA despite their substantial differences in structure and efficacy (Fig. 5) . 294
Search related documents:
Co phrase search for related documents- antiviral therapeutic and data analysis: 1, 2
- antiviral therapeutic and efficacy structure: 1
- antiviral therapeutic and host factor: 1, 2, 3, 4, 5
- antiviral therapeutic and PCA principal component analysis: 1
- antiviral therapeutic and principal component analysis: 1, 2
- antiviral therapeutic and therapeutic class: 1
- antiviral therapeutic class and host factor: 1
- antiviral therapeutic class and therapeutic class: 1
- component analysis and data analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- component analysis and data analysis pipeline: 1
- component analysis and host factor: 1
- component analysis and PCA principal component analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- component analysis and principal component analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- data analysis and efficacy structure: 1
- data analysis and host factor: 1, 2, 3, 4, 5, 6, 7
- data analysis and major finding: 1, 2
- data analysis and PCA principal component analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- data analysis and principal component analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- data analysis and substantial difference: 1
Co phrase search for related documents, hyperlinks ordered by date